Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma.

Oncotarget - 19 Jul 2024

Valdez Caroline Naomi, Sánchez-Zuno Gabriela Athziri, Osmani Lais, Ibrahim Wael, Galan Anjela, Bacchiocchi Antonietta, Halaban Ruth, Kulkarni Rajan P, Kang Insoo, Bucala Richard, Tran Thuy

Abstract excerpt

Macrophage Migration Inhibitory Factor (MIF) and its homolog D-dopachrome Tautomerase (DDT) have been implicated as drivers of tumor progression across a variety of cancers. Recent evidence suggests MIF as a therapeutic target in immune checkpoint inhibition (ICI) resistant melanomas, however clinical evidence of MIF and particularly of DDT remain limited. This retrospective study analyzed 97 patients treated at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Differentiation, B-Lymphocyte
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histocompatibility Antigens Class II

Share to Immune Checkpoint Inhibitors

Share to Intramolecular Oxidoreductases

Share to Macrophage Migration-Inhibitory Factors

Share to Melanoma

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 39028303
DOI: 10.18632/oncotarget.28615
PMCID: PMC11259151

Genes

DDT
MIF
CD74

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma.PMID 39028303Read ↗

Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.Semantic proximity Read ↗

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma.Semantic proximity Read ↗

Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary MelanomaSemantic proximity Read ↗

Impact of Sequencing Radiation Therapy and Immune Checkpoint Inhibitors in the Treatment of Melanoma Brain MetastasesSemantic proximity Read ↗

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.Semantic proximity Read ↗

Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapySemantic proximity Read ↗

PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockadeSemantic proximity Read ↗

RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma.Semantic proximity Read ↗

Differentiation status determines the effects of IFNγ on the expression of PD-L1 and immunomodulatory genes in melanomaSemantic proximity Read ↗

Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients.Semantic proximity Read ↗

Decitabine suppresses MDSC-induced immunosuppression through dual functional mechanism and inhibits melanoma metastasisSemantic proximity Read ↗

Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti–PD-1 therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.